

Aimee C Talleur

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5534348/publications.pdf>

Version: 2024-02-01

42
papers

494
citations

840776

11
h-index

752698

20
g-index

44
all docs

44
docs citations

44
times ranked

554
citing authors

#	ARTICLE	IF	CITATIONS
1	Allogeneic CAR Cell Therapyâ€”More Than a Pipe Dream. <i>Frontiers in Immunology</i> , 2020, 11, 618427.	4.8	64
2	Hemophagocytic lymphohistiocytosisâ€”like toxicity (carHLH) after CD19â€”specific CAR Tâ€”cell therapy. <i>British Journal of Haematology</i> , 2021, 194, 701-707.	2.5	61
3	CD19-CAR Tâ€”cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia. <i>Cell Reports</i> , 2021, 37, 110079.	6.4	48
4	Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colonyâ€”Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1910-1917.	2.0	35
5	Improved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institution. <i>Bone Marrow Transplantation</i> , 2020, 55, 929-938.	2.4	31
6	Limited Margin Radiation Therapy for Children and Young Adults With Ewing Sarcoma Achieves High Rates of Local Tumor Control. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 119-126.	0.8	28
7	Treatment intensity and symptom burden in hospitalized adolescent and young adult hematopoietic cell transplant recipients at the end of life. <i>Bone Marrow Transplantation</i> , 2018, 53, 84-90.	2.4	26
8	Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor Lineages. <i>Cancer Discovery</i> , 2022, 12, 2098-2119.	9.4	24
9	Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. , 2020, 8, e001563.		22
10	Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 73.e1-73.e9.	1.2	20
11	Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL. <i>Blood Advances</i> , 2022, 6, 5737-5749.	5.2	20
12	Anakinra utilization in refractory pediatric CAR T-cell associated toxicities. <i>Blood Advances</i> , 2022, 6, 3398-3403.	5.2	17
13	Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial. , 2020, 8, e000176.		14
14	Thoughts from the threshold: patient and family hopes, fears, values, and goals at the onset of pediatric hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1103-1113.	2.4	13
15	Infectious Complications in Pediatric, Adolescent and Young Adult Patients Undergoing CD19-CAR T Cell Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 845540.	2.8	10
16	Outcomes of pediatric patients who relapse after first HCT for acute leukemia or MDS. <i>Bone Marrow Transplantation</i> , 2021, 56, 1866-1875.	2.4	7
17	Extracorporeal Membrane Oxygenation Candidacy in Pediatric Patients Treated With Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy: An International Survey. <i>Frontiers in Oncology</i> , 2021, 11, 798236.	2.8	7
18	Autologous hematopoietic cell transplantation for the treatment of relapsed/refractory pediatric, adolescent, and young adult Hodgkin lymphoma: a single institutional experience. <i>Bone Marrow Transplantation</i> , 2020, 55, 1357-1366.	2.4	6

#	ARTICLE	IF	CITATIONS
19	Chimeric Antigen Receptor T-cell Therapy. Hematology/Oncology Clinics of North America, 2022, 36, 701-727.	2.2	6
20	Evidence-Based Minireview: What is the role for HSCT or immunotherapy in pediatric hypodiploid B-cell acute lymphoblastic leukemia?. Hematology American Society of Hematology Education Program, 2020, 2020, 508-511.	2.5	4
21	Development of a cGMP-compliant process to manufacture donor-derived, CD45RA-depleted memory CD19-CAR T cells. Gene Therapy, 2023, 30, 222-231.	4.5	4
22	A quality improvement project to improve pediatric medical provider sleep and communication during night shifts. International Journal for Quality in Health Care, 2019, 31, 633-638.	1.8	3
23	Secondary hemophagocytic syndrome after autologous hematopoietic cell transplant and immune therapy for neuroblastoma. Pediatric Blood and Cancer, 2019, 66, e27964.	1.5	3
24	Haploidentical CD45RA-Negative Donor Lymphocyte Infusions Are Feasible, Safe and Associated with Clinical Benefit. Biology of Blood and Marrow Transplantation, 2020, 26, S268.	2.0	3
25	Allogeneic Hematopoietic Cell Transplantation Is Critical to Maintain Remissions after CD19-CAR T-Cell Therapy for Pediatric ALL: A Single Center Experience. Blood, 2020, 136, 39-40.	1.4	3
26	CD45RA-Depleted Haploidentical Transplantation Combined with NK Cell Addback Results in Promising Long-Term Outcomes in Pediatric Patients with High-Risk Hematologic Malignancies. Blood, 2021, 138, 172-172.	1.4	3
27	Treatment patterns and disease outcomes for pediatric patients with refractory or recurrent Hodgkin lymphoma treated with curative-intent salvage radiotherapy. Radiotherapy and Oncology, 2019, 134, 89-95.	0.6	2
28	Hematopoietic cell transplant for reversal of liver fibrosis in a pediatric patient with erythropoietic protoporphyria. Pediatric Transplantation, 2021, 25, e13966.	1.0	2
29	CD45RO+ T-Cell Add Back and Prophylactic Blinatumomab Administration Post Tcr $\alpha\beta$ /CD19-Depleted Haploidentical Transplantation in Pediatric Patients with High Risk Acute Leukemia. Blood, 2021, 138, 2897-2897.	1.4	2
30	Autologous CD19-CAR T-Cells for the Treatment of Acute Lymphoblastic Leukemia in Pediatric and Young Adult Patients: An initial Report from an Institutional Phase I/II Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S265.	0.4	1
31	Allogeneic CD45RA-depleted cells in adoptive cell therapy. Advances in Cell and Gene Therapy, 2019, 2, e45.	0.9	1
32	Sub-myeloablative Second Transplantations with Haploidentical Donors and Post-Transplant Cyclophosphamide have limited Anti-Leukemic Effects in Pediatric Patients. Transplantation and Cellular Therapy, 2022, 28, 262.e1-262.e10.	1.2	1
33	Venetoclax-Based Combination Therapy As a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Children with Relapsed/Refractory AML. Transplantation and Cellular Therapy, 2022, 28, S120-S121.	1.2	1
34	1184 PAGING ACTIVITY AND SLEEP DISRUPTIONS FOR MEDICAL RESIDENTS DURING OVERNIGHT SHIFTS. Sleep, 2017, 40, A442-A442.	1.1	0
35	Second Allogeneic Hematopoietic Cell Transplant Is a Successful Salvage Modality for Pediatric Patients Who Relapse after First Transplant. Biology of Blood and Marrow Transplantation, 2020, 26, S85-S86.	2.0	0
36	Autologous Hematopoietic Cell Transplantation without Transfusion in a Teenage Jehovah's Witness: A Case Report from a Pediatric Transplant Center. Biology of Blood and Marrow Transplantation, 2020, 26, S137.	2.0	0

#	ARTICLE	IF	CITATIONS
37	Infectious Outcomes in Pediatric Patients Undergoing CD19-CAR T Cell Therapy â€” a Single Center Experience. <i>Transplantation and Cellular Therapy</i> , 2021, 27, S211.	1.2	0
38	Chimeric antigen receptor engineered allogeneic CD27-negative T cells for the treatment of CD19+ leukemia.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3046-3046.	1.6	0
39	Sequential Infusion of Tcr $\alpha\beta$ - and CD45RA-Depleted Haploidentical Progenitor Cells Is Safe and Allows for Rapid Immune Reconstitution in Pediatric Patients with Recurrent Hematological Malignancies. <i>Blood</i> , 2018, 132, 4574-4574.	1.4	0
40	CD19-CAR T Cells Develop Exhaustion Epigenetic Programs during a Clinical Response. <i>Blood</i> , 2021, 138, 2782-2782.	1.4	0
41	152â€¦Common trajectories of highly effective anti-CD19 chimeric antigen receptor-modified T cells identified by endogenous T cell receptor lineages. , 2021, 9, A160-A161.		0
42	Bone mineral density (BMD) deficits in adult survivors of childhood cancer: Attributable risks and long-term consequences.. <i>Journal of Clinical Oncology</i> , 2022, 40, e22021-e22021.	1.6	0